Catalent Inc (CTLT) Insider Sells $1,968,114.60 in Stock
Catalent Inc (NYSE:CTLT) insider Barry Littlejohns sold 47,265 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $41.64, for a total transaction of $1,968,114.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
NYSE:CTLT traded up $0.30 during trading hours on Wednesday, hitting $43.18. 10,767 shares of the company were exchanged, compared to its average volume of 943,146. Catalent Inc has a one year low of $36.73 and a one year high of $47.87. The company has a quick ratio of 1.79, a current ratio of 2.15 and a debt-to-equity ratio of 2.44. The firm has a market cap of $6.61 billion, a P/E ratio of 27.01, a P/E/G ratio of 2.71 and a beta of 1.40.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.06. Catalent had a return on equity of 20.42% and a net margin of 3.39%. The business had revenue of $685.30 million during the quarter, compared to the consensus estimate of $690.69 million. During the same quarter in the previous year, the business earned $0.65 EPS. The company’s quarterly revenue was up 11.1% on a year-over-year basis. As a group, equities research analysts expect that Catalent Inc will post 1.72 EPS for the current year.
Several equities research analysts have weighed in on the company. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, July 3rd. JPMorgan Chase & Co. raised their price target on Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 29th. Finally, UBS Group started coverage on Catalent in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price objective on the stock. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Catalent presently has a consensus rating of “Buy” and an average price target of $49.33.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: Stop Order
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.